1. Home
  2. EXAS vs NVVEW Comparison

EXAS vs NVVEW Comparison

Compare EXAS & NVVEW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

HOLD

Current Price

$101.58

Market Cap

11.0B

Sector

Health Care

ML Signal

HOLD

Logo Nuvve Holding Corp. Warrant

NVVEW

Nuvve Holding Corp. Warrant

N/A

Current Price

$0.01

Market Cap

0.0

Sector

Energy

ML Signal

N/A

Company Overview

Basic Information
Metric
EXAS
NVVEW
Founded
1995
N/A
Country
United States
China
Employees
N/A
12
Industry
Medical Specialities
Oil Refining/Marketing
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
11.0B
N/A
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
EXAS
NVVEW
Price
$101.58
$0.01
Analyst Decision
Buy
Analyst Count
20
0
Target Price
$77.94
N/A
AVG Volume (30 Days)
10.8M
N/A
Earning Date
11-03-2025
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,082,033,000.00
N/A
Revenue This Year
$19.40
N/A
Revenue Next Year
$13.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
14.47
N/A
52 Week Low
$38.81
N/A
52 Week High
$101.95
N/A

Technical Indicators

Market Signals
Indicator
EXAS
NVVEW
Relative Strength Index (RSI) 89.65 38.66
Support Level $100.95 $0.01
Resistance Level $101.95 $0.02
Average True Range (ATR) 0.35 0.00
MACD -0.87 -0.00
Stochastic Oscillator 61.17 16.51

Price Performance

Historical Comparison
EXAS
NVVEW

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

About NVVEW Nuvve Holding Corp. Warrant

Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.

Share on Social Networks: